I wanted to take part in this because Propel was there for me (like you guys) since day 1. We all know what Crohn's all about so no need to rehash. I hope and pray that Propel's effort will produce meaningful changes and they have my full support.
|Dr. Mark Silverberg is the director of the Toronto Immune and Digestive Health Center and is a professor at the Department of Medicine at the University of Toronto. He leads a clinical research program that focuses on the causes of IBD, the development of tools to improve the management of IBD patients, and the development of novel IBD therapies. He has contributed to the discovery of genes related to IBD as well as being a major contributor to the field of classification of IBD.|
Dr. Séverine Vermeire is affiliated with the Gastroenterology Department of the University Hospitals in Leuven, Belgium, and is also a professor of medicine at the Catholic University of Belgium. Her work has focused on the genetics and pharmacogenetics of IBD, on the role of the microbiome in IBD, and on aspects related to the immunogenicity of biological therapies.
Dr. Bram Verstockt is a gastroenterologist holding positions as a clinician and researcher in both the Department of Gastroenterology and Hepatology and the Department of Chronic Diseases and Metabolism at the University Hospitals in Leuven, Belgium. He is interested in translational research focusing primarily on the development of predictive and prognostic markers as part of a precision approach, and also utilizes mult-omics as a tool.